Welcome to Markets Desk, your midday read on what's moving markets and why.
In the venture and tech space, a sharp note out of Fortune is pushing back on the AI productivity boom, arguing that the world is drowning in redundant tools and that the vast majority of triple-digit startups evaluated in the past year alone are headed for zero. The message to investors is clear: capital is misallocated, and the correction will be painful.
Shifting to healthcare, Lupin has inked a strategic partnership with Tenpoint Therapeutics to bring YUVEZZI across Europe, covering the European Union, the United Kingdom, Switzerland, Norway, and Iceland. YUVEZZI holds the distinction of being the first and only once-daily dual-agent eye drop approved for presbyopia, and this deal marks a meaningful commercial expansion for Lupin beyond its traditional generics base.
And in the earnings column, Bavarian Nordic delivered a strong second quarter, posting revenue growth of twenty-three percent to just over two billion Danish kroner, with an EBITDA margin of forty-five percent. The Danish biotech upgraded its full-year two thousand twenty-six guidance and announced it will initiate a share buyback program, signaling management confidence in the trajectory ahead.
That's the tape. Markets Desk, signing off the floor.
